-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25

Benzinga·11/11/2026 17:59:21
Listen to the news
Oppenheimer analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Perform and lowers the price target from $40 to $25.